Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The cyclin-dependent kinase (Cdk) inhibitor p27 regulates cell proliferation, cell motility and apoptosis, and is inactivated through various means in many types of human cancer. Recent studies in several tumour types indicate that p27 expression levels have both prognostic and therapeutic implications.
Testing for prostate-specific antigen is a powerful tool in the detection of prostate cancer, but how should it be used and how can testing be improved to ensure against overdiagnosis?
This Review examines whether GATA1-related leukaemias in both human and mouse can provide important insights into the mechanism of multi-step leukaemogenesis.
One explanation for the relative lack of progress in treating cancer in adolescents and young adults is that the biology of malignant diseases in this age group is different. Do molecular, epidemiological and therapeutic outcome comparisons support this?
Adoptive cell therapy (ACT), using either autologous tumour-infiltrating lymphocytes or donor lymphocytes, has proved an effective treatment for some patients with advanced cancers. Can the ability to genetically engineer human lymphocytes for ACT further expand the use of this treatment?
Making multidisciplinary translational clinical trials work successfully is complex and challenging. Rakesh Jain presents his perspective on the lessons he and his team have learned from two such trials in patients with advanced rectal cancer or glioblastoma.
